2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Sunday, October 21, 2018

9:00AM-11:00AM: Abstract Number: 526

Bronchiectasis in RA Is a Crucial Risk Factor of Hospitalised Pneumonia Associated with Bdmards As Well As Interstitial Lung Disease

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

9:00AM-11:00AM: Abstract Number: 300

Built-in-Electronic-Medical-Record Disease Activity Calculators and Treat-to-Target in Rheumatoid Arthritis

Health Services Research Poster I – ACR/ARHP

9:00AM-11:00AM: Abstract Number: 288

Burden of Illness of Treating Patients with Pemphigus vulgaris

Health Services Research Poster I – ACR/ARHP

9:00AM-11:00AM: Abstract Number: 139

Calcium/Calmodulin-Dependent Protein Kinase 4 Promotes GLUT1-Dependent Glycolysis in Systemic Lupus Erythematosus

T Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 650

Can Disease Activity in Patients with Psoriatic Arthritis be Adequately Assessed By a Modified Disease Activity Index for Psoriatic Arthritis (DAPSA) Based on 28 Joints?

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

9:00AM-11:00AM: Abstract Number: 740

Can Monocyte Chemo-Attractant Protein-1differentiate Different Histological Classes in Lupus Nephritis?

Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

9:00AM-11:00AM: Abstract Number: 566

Capillary Blood Based Methotrexate Polyglutamate Assay for Monitoring Low Dose Methotrexate Therapy in Rheumatic Diseases

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

9:00AM-11:00AM: Abstract Number: 33

Card9 Is a Critical Regulator of Autoimmune Arthritis in SKG Mice

Rheumatoid Arthritis – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 801

Cardiac Autonomic Modulation at Rest and during Orthostatic Stress in Systemic Sclerosis Patients

Systemic Sclerosis and Related Disorders – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 518

Cardiometabolic Risk Factors Impact on the Cardioprotective Effect of Apelin on Systolic and Diastolic Function, in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

9:00AM-11:00AM: Abstract Number: 764

Cardiovascular Disease in SLE at One Center between 1981 and 2016. a Population-Based Study Highlighting the Importance of Disease Duration and Age at Diagnosis

Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

9:00AM-11:00AM: Abstract Number: 509

Cardiovascular Disease Risk Factors May Negatively Impact Rheumatoid Arthritis Disease Outcomes: Findings from the Ontario Best Practices Research Initiative

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

9:00AM-11:00AM: Abstract Number: 514

Cardiovascular Risk Management in Seropositive Rheumatoid Arthritis: What Can We Do Better?

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

9:00AM-11:00AM: Abstract Number: 741

Cardiovascular Risk Re-Classification Using Carotid Ultrasound in Systemic Lupus Erythematosus Patients Is Related to the Damage Produced By the Disease

Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

9:00AM-11:00AM: Abstract Number: 308

Carpal Bones Affectation Frequency in Rheumatoid Arthritis By Magnetic Resonance Imaging

Imaging of Rheumatic Diseases Poster I: MRI

«Previous Page
1
…
6
7
8
9
10
…
67
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].